Cerebrolysin for acute ischaemic stroke

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 4, 2017, Pages

  Ziganshina, Liliya Eugenevna ^a   Abakumova, Tatyana ^a   Vernay, Ludivine ^b  

^a KAZAN FEDERAL UNIVERSITY   (Russian Federation)

^b ECOLE DES MINES D ALBI CARMAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROLYSIN;

BRAIN ISCHEMIA; CAUSE OF DEATH; CLINICAL OUTCOME; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; THERAPY EFFECT;

EID: 85018493408     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007026.pub5     Document Type: Review

References (144)

1. Amiri-Nikpour MR, Nazarbaghi S, Ahmadi-Salmasi B, Mokari T, Tahamtan U, Rezaei Y. Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment 2014;10:2299-306. 4479442
2. Bornstein NM. CASTA - the background for the study and protocol design. International Journal of Stroke 2010;5(Suppl 2):50. 2799412
3. Brainin M, Heiss WD, Bornstein N, Tuomilehto J, Hong Z. CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases 2012;33(Suppl 2):459-60. 4479443
4. Heiss WD, Brainin M, Bornstein N, Zhen H. Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke 2010;5(Suppl 2):71. 4479444
5. Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke 2012;43(3):630-6. 2799415
6. Hong Z, Moessler H, Bornstein N, Brainin M, Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke 2009;4(5):406-12. 4479445
7. Zhen H. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). www.ClinicalTrials.gov 2014. 4479446
8. Lang W, Stadler CH, Poljakovic Z, Fleet D, Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke 2012;8(2):95-104. 4479447
9. Windisch M, Lang W. Combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischemic hemispheric stroke (CERE-LYSE-1). www.ClinicalTrials.gov 2014. 4479448
10. Ladurner G. Neuroprotection in acute ischaemic stroke. Stroke 2001 2001;32:323. 4479450
11. Ladurner G, Gmeinbauer R, Moessler H. Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases 2001;11(4):75. 2799404
12. Ladurner G, Kalvach P, Moessler H, Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission 2005;112(3):415-28. 4479449
13. Skvortsova VI, Shamalov NA, Stakhovskaya LV, Gubsky LV, Tikhonova IV, Smichkov AS. Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases 2005;19(Suppl 2):76. 2799458
14. Skvortsova VI, Stakhovskaia LV, Gubskii LV, Shamalov NA, Tikhonova IV, Smychkov AS. A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov 2004;Suppl 11:51-5. 4479451
15. Skvortsova VI, Stakhovskaya LV, Gubsky LV, Shamalov NA, Tikhonova IV, Smychkov AS. Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Recept] 2007;5(55):94-8. 4479452
16. Xue LX, Zhang T, Zhao YW, Geng Z, Chen JJ, Chen H. Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine 2016;11(5):2015-20. 4479454
17. Barolin GS, Koppi S, Kapeller E. Old and new aspects of stroke treatment with emphasis on metabolically active medication and rehabilitative outcome. Eurorehab 1996;3:135-43. 4479456
18. Bavarsad Shahripour R, Shalil Ahmadi A. The efficacy of cerebrolysin in patients with acute ischemic stroke. Proceedings of the 20th European Stroke Conference. 2011 May 24-27; Hamburg, Germany 2011. 4479457
19. Bayer E. Therapeutic use of a brain hydrolysate. Medizinische Welt 1980;31(17):636-7. 4479459
20. Belkin AA. Navigation brain stimulation for evaluation of the neuroprotective drug efficiency in patients after ischemic stroke. ClinicalTrials.gov (accessed 19 July 2016). 4479461
21. Belkin AA, Alasheev AM. Comprehensive reparative therapy in ischemic stroke complex repair in ischemic stroke - arm. ClinicalTrials.gov Accessed 19 July 2016. 4479463
22. Chang WH, Park CH, Kim DY, Shin YI, Ko MH, Lee A, et al. Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke. Effects of cerebrolysin on motor recovery in patients with subacute stroke (E-COMPASS). BMC Neurology 2016;2(16):31. [DOI: 10.1186/s12883-016-0553-z]4479465
23. Cuparnecu B. Efficacy of cerebrolysin in patients with ischaemic stroke of the middle cerebral artery. Pharmacology and Toxicology 2001;89 Suppl 1:136. 4479466
24. Domzal T, Zaleska B. Cerebrolysin in treatment of acute ischemic stroke. Neurologia i Neurochirurgia Polska 1995;29(3):325-31. 4479468
25. Kim YH. Effects of cerebrolysin combined with rehabilitation on motor recovery in stroke. www.strokecenter.org (accessed 18 July 2016). 4479470
26. Ershov VI. Comparative aspects of using neuroprotectors in the management of patients with ischemic stroke. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova 2011;111(8 Pt 2):41-4. 4479471
27. Ershov VI. Comparative characteristics of efficacy of neuroprotectors for treating ischaemic stroke. Nevrologichesky Vestnik. Zhurnal im. VM Bekhtereva 2009;41(3):65-9. 4479472
28. Guekht A, Heiss WD, Bajenaru OA, Popescu C, Gusev E, Vester JC, et al. Cerebrolysin and recovery after stroke (CARS): a meta-analysis of two randomized, controlled, double-blind trials assessing the combination of Cerebrolysin and standardized rehabilitation on motor recovery. European Journal of Neurology 2015;22:598. 4479474
29. Guekht A, Heiss D, Gusev E, Vester J, Doppler E, Muresanu D. Cerebrolysin and recovery after stroke (CARS 2): a randomized, placebo-controlled, double-blind, multicenter clinical study. Journal of the Neurological Sciences 2015;357:e103. 4479476
30. Haffner Z, Gmeinbauer R, Moessler H. A randomized, double-blind, placebo-controlled trial with cerebrolysin in acute ischaemic stroke. Cerebrovascular Diseases 2001;11 Suppl 4:76. 4479477
31. Jianu DC, Muresanu DF, Bajenaru O, Popescu BO, Deme SM, Moessler H, et al. Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery. Journal of Medicine and Life 2010;3(3):297-307. 2799435
32. Jianu DC, Jianu SN, Petrica L, Deme SM, Dan F, Falup Pecurariu C, et al. Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery. International Journal of Stroke 2015;10:187. 4479479
33. Kim YH, Kim DY, Shin YI, Ko MH, Chang WH, Lee AH. Effects of cerebrolysin on motor recovery in patients with subacute stroke. International Journal of Stroke 2014;9:107-8. 4479480
34. Kim YH, Park CH, Kim DY, Shin YI, Ko MH, Chang WH, et al. Effects of cerebrolysin on motor recovery of stroke patients: a diffusion tensor imaging study. International Journal of Stroke 2014;9:49-9. 4479481
35. Kim YH, Kim DY, Shin YI, Ko MH, Chang WH, Lee AH. Effects of cerebrolysin on motor recovery in patients with severe stroke motor impairment after stroke. International Journal of Stroke 2015;10(Suppl 2):90. 4479483
36. Martinez Sanchez BR, Hernandez Hernandez JJ, Franco Del Aguila DI, Gryzbowski Gainza E, Paz Ballesteros WC, Herrera Rojas J, et al. An open label, one arm study to evaluate the efficacy and safety of cerebrolysin in patients with acute severe ischemic stroke in Mexico. Value in Health 2015;18(7):A827-8. 4479485
37. Muresanu D, Heiss WD, Bajenaru O, Popescu CD, Vester J, Guekht A. Cerebrolysin and recovery after stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter, phase II clinical study. International Journal of Stroke 2015;10(Suppl 2):92. 4479487
38. Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, et al. Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke 2016;47(1):151-9. 4479488
39. Pushkarev K, Tsoy R. Neuroprotective therapy for lacunar stroke - which is better Ceraxon or Cerebrolysin?. European Journal of Neurology 2015;22:775. 4479490
40. Shamalov NA, Stakhovskaya LV, Gubsky LV, Tikhonova IV, Smichkov AS, Skvortsova VI, et al. Effects of the neuroprotective drug cerebrolysin on the infarct volume after acute ischemic stroke. Cerebrovascular Diseases 2005;19 Suppl 2:107. 4479491
41. Shamalov NA, Stakhovskaia LV, Burenchev DV, Kichuk IV, Tvorogova TV, Botsina AI, et al. The effect of cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov 2010;110(12 Pt 2):34-7. 4479492
42. Shishkova V, Zotova LI, Remennik AYU. Association between BDNF-196 G>A and BDNF-270 C>T polymorphisms, BDNF concentration, and cerebrolysin treatment outcome after ischemic stroke. International Journal of Stroke 2015;10 Suppl 2:170. 4479494
43. Skvortsova VI, Stakhovskaia LV, Shamolov NA, Kerbikov OB. Results of the multicenter prospective study of cerebrolysin safety and efficacy in acute stroke. Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsakova 2006;Suppl 16:41-5. 4479495
44. Stan AD, Badisor A, Birle C, Blesneag AV, Opincariu I, Iancu M, et al. The influence of neurotrophic factors treatment on stroke volume. Romanian Journal of Neurology 2013;XII(3):124-9. 4479496
45. Vilenskii BS, Semenova GM, Shirokov EA. The application of cerebrolysine in ischemic stroke. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov 1999;99(4):65-9. 4479498
46. Yavorskaya VA, Bondar OB. Clinical features of cerebrolysin application in patients in acute period of ischemic stroke. International Journal of Stroke 2008;3 Suppl 1:141. 4479499
47. Zhu GX, Hong Z, Yao JL, Yu LY. Double-blind and randomized placebo-controlled trial of cerebrolysin in improvement of nerve function and living ability in patients with ischemic stroke. Chinese Journal of Clinical Rehabilitation 2003;7(22):3084-5. 4479500
48. Dobi D, Xhaxho S, Kapisyzi M, Papadhopulli Z. The effect of cerebrolysin in acute ischemic stroke. Revue Neurologique 2010;166(3):355. 4479502
49. Hong Z, Zhu G, Chen H. The clinical efficacy of cerebrolysin in the treatment of acute ischemic stroke. Chinese Journal of Geriatric Heart Brain and Vessel Diseases 2005;7(5):331-3. 4479503
50. IRCT138803272042N1 . The efficacy of cerebrolysin in the treatment of acute ischemic stroke. Iranian Registry of Clinical Trials (en.search.irct.ir/view/1090) (accessed 15 December 2014). 2799492
51. Nazarbaghi S, Nikpoor MA. Efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke 2014;9 Suppl 3:91-2. 4479504
52. Jech M, Shamalov NA, Moessler H, Skvortsova VI. Safety and efficacy of cerebrolysin as adjuvant therapy in patients suffering from acute ischemic stroke. Cerebrovascular Diseases 2009;27(Suppl 6):84. 4479505
53. Skvortsova VI, Shamalov NA, Moessler H, Doppler E. Safety and efficacy of cerebrolysin as adjuvant therapy in patients suffering from acute ischemic stroke. European Journal of Neurology 2008;15 Suppl 3:253. 4479506
54. Skvortsova VI, Shamalov NA, Moessler H, Novak PH. Beneficial effects of the neurotrophic drug cerebrolysin on the infarct volume after acute stroke. Cerebrovascular Diseases 2008;25 Suppl 2:145. 4479507
55. Skvortsova VI, Shamalov NA, Moessler H, Novak PH. Positive impacts of the neurotrophic drug cerebrolysin on the infarct volume after acute stroke. International Journal of Stroke 2008;3 Suppl 1:137. 4479508
56. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke disease statistics - 2014 update: a report from the American Heart Association. Circulation 2014;129(3):e28-e292.
57. Alper BS, Malone-Moses M, McLellan JS, Prasad K, Manheimer E. Thrombolysis in acute ischaemic stroke: time for a rethink?. BMJ 2015;350:h1075. [DOI: http://dx.doi.org/10.1136/bmj.h1075]
58. Alvarez XA, Lombardi VR, Corzo L, Pérez P, Pichel V, Laredo M, et al. Oral cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects. Journal of Neural Transmission 2000;59 Suppl:315-28.
59. Appelros P, Terént A. Thrombolysis in acute stroke. Lancet 2015;385(9976):1394. [DOI: http://dx.doi.org/10.1016/S0140-6736(15)60714-0]
60. Bajenaru O, Tiu C, Moessler H, Antochi F, Muresanu D, Popescu BO, et al. Efficacy and safety of cerebrolysin in patients with hemorrhagic stroke. Journal of Medicine and Life 2010;3(2):137-43.
61. Blood pressure in Acute Stroke Collaboration (BASC). Vasoactive drugs for acute stroke. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD002839]
62. Blood pressure in Acute Stroke Collaboration (BASC). Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database of Systematic Reviews 2001, Issue 3. [DOI: 10.1002/14651858.CD000039]
63. Bath PMW, Willmot M, Leonardi-Bee J, Bath-Hextall FJ. Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD000398]
64. Bath PMW. Theophylline, aminophylline, caffeine and analogues for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD000211.pub2]
65. Bath PMW, Bath-Hextall FJ. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD000162.pub2]
66. Bath PMW. Prostacyclin and analogues for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD000177.pub2]
67. Bath PMW, Sprigg N, England T. Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD005207.pub4]
68. Bath PMW, Krishnan K. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD000039.pub3]
69. Bereczki D, Fekete I, Prado GF, Liu M. Mannitol for acute stroke. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD001153.pub2]
70. Bereczki D, Fekete I. Vinpocetine for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD000480.pub2]
71. Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD003242]
72. Boncoraglio GB, Bersano A, Candelise L, Reynolds BA, Paratti EA. Stem cell transplantation for ischemic stroke. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD007231.pub2]
73. Bonita R. Epidemiology of stroke. Lancet 1992;339(8789):342-4.
74. Brunström M, Carlberg B. Thrombolysis in acute stroke. Lancet 2015;385(9976):1394-5. [DOI: http://dx.doi.org/10.1016/S0140-6736(15)60715-2]
75. Candelise L, Ciccone A. Gangliosides for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD000094]
76. Chang TS, Jensen MB. Haemodilution for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD000103.pub2]
77. Chen X, Zhou M, Li Q, Yang J, Zhang Y, Zhang D, et al. Sanchi for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD006305.pub2]
78. Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD008900.pub2]
79. Chukanova EI. The effect of cerebrolysin on the clinical symptoms and the course of ischemic encephalopathy. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 2005;105(1):42-5.
80. Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD005208.pub3]
81. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
82. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384(9958):1929-35.
83. The European Ad Hoc Consensus Group. Neuroprotection as initial therapy in acute stroke. Third report of an Ad Hoc Consensus Group Meeting. Cerebrovascular Diseases 1998;8(1):59-72.
84. Feng S, Yang Q, Liu M, Li W, Yuan W, Zhang S, et al. Edaravone for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD007230.pub2]
85. Fragoso Y, Dantas DC. Cerebrolysin for Alzheimer's disease. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003801]
86. French B, Thomas LH, Leathley MJ, Sutton CJ, McAdam J, Forster A, et al. Repetitive task training for improving functional ability after stroke. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD006073]
87. Gafurov BG, Alikulova NA. Clinical and pathogenetical peculiarities and treatment policy in ischemic stroke of elderly and old age [Russian]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 2004;104 Suppl 11:44-6.
88. Gandolfo C, Sandercock P, Conti M. Lubeluzole for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD001924]
89. Essential Medicines List for 2016. Government of the Russian Federation RASPORIESE 26 December 2015. government.ru/media/files/MzyV0Mmm2FoDAP7AWAAVLLpjoLoiShib.pdf (accessed 12 August 2016).
90. McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org. GRADEPro Guideline Development Tool. McMaster University (developed by Evidence Prime, Inc.). Available from www.gradepro.org, 2015.
91. Gromova OA, Tret'iakov VE, Moshkovski SA, Gusev EI, Nikonov AA, Val'kova LA, et al. An oligopeptide membrane fraction of cerebrolysin. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova 2006;106(7):68-70.
92. Gusev EI, Skvortsova VI, Stakhovskaia LV. Epidemiology of stroke in Russia. Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova 2003;Suppl 8:4-9.
93. Gusev EI, Martynov MYu, Kamtchatnov PR. Ischemic stroke: current status [Ishemichesky insult. Sovremennoye sostoyaniye problemy]. Nevrologiya 2013;83(5):2-7.
94. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
95. Hao Z, Liu M, Counsell C, Wardlaw JM, Lin S, Zhao X. Fibrinogen depleting agents for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD000091.pub2]
96. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
97. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
98. Hong Z, Moessler H, Bornstein N, Brainin M, Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke 2009;4(5):406-12.
99. Horn J, Limburg M. Calcium antagonists for acute ischemic stroke. Cochrane Database of Systematic Reviews 2000, Issue 1. [DOI: 10.1002/14651858.CD001928]
100. ICH Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Post-approval safety data management: definitions and standards for expedited reporting E2D. ICH harmonised tripartite guideline, Step 4 version 2003.
101. Leonardi-Bee J, Steiner T, Bath-Hextall F. Naftidrofuryl for acute stroke. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD005478.pub2]
102. Liu J, Wang LN, Ma X, Ji X. Gamma aminobutyric acid (GABA) receptor agonists for acute stroke. Cochrane Database of Systematic Reviews 2016, Issue 10. [DOI: 10.1002/14651858.CD009622.pub4]
103. Makarenko AN, Kositsin NS, Nazimov IV, Svinov MM, Goloborod'ko EV, Pasikova NV. A comparative study of antistroke activity of the new drug "cerebral" and its fractions in rats. Eksperimental'naia i Klinicheskaia Farmakologiia 2005;68(2):15-20.
104. Martynchik SA, Sokolova OV. Medical and economic assessment and rationale for improving organization of inpatient care for cerebral stroke [Medico-economicheskaya otsenka i obosnovaniye sovershenstvovaniya organizatsionnykh form okazaniya stacionarnoy pomoschi pri mozgovom insulte]. Social Aspects of Population Health (vestnik.mednet.ru/content/view/473/30/lang.ru/) 2013; Vol. 30, issue 2.
105. Masliah E, Díez-Tejedor E. The pharmacology of neurotrophic treatment with cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs of Today 2012;48(Suppl A):3-24. [DOI: 10.1358/dot.2012.48(Suppl.A).1739716]
106. MedDRA Maintenance and Support Services Organization. Introductory Guide to MedDRA Version 14.0. Chantilly, Virginia, March, 2011.
107. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357(9263):1191-4.
108. Muir KW, Lees KR. Excitatory amino acid antagonists for acute stroke. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD001244]
109. O'Rourke K, Berge E, Walsh CD, Kelly PJ. Percutaneous vascular interventions for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2010, Issue 10. [DOI: 10.1002/14651858.CD007574.pub2]
110. Onishchenko LS, Ga kova ON, Ianishevski SN. Changes in the focus of experimental ischemic stroke under the influence of neuroprotective drugs. Morfologiia 2006;130(6):40-6.
111. Registry of Medicines. Cerebrolysin. www.rlsnet.ru/tn_index_id_3528.htm#pobochnye-dejstviya (accessed 31 January 2015).
112. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
113. Ricci S, Celani MG, Cantisani TA, Righetti E. Piracetam for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD000419.pub3]
114. Ricci S, Dinia L, Del Sette M, Anzola P, Mazzoli T, Cenciarelli S, et al. Sonothrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD008348.pub3]
115. Righetti E, Celani MG, Cantisani T, Sterzi R, Boysen G, Ricci S. Glycerol for acute stroke. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD000096.pub2]
116. Riley C, Hutter-Paier B, Windisch M, Doppler E, Moessler H, Wronski R. A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication. Journal of Neural Transmission 2006;113(1):103-10.
117. Sandercock PAG, Counsell C, Kamal AK. Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD000024.pub3]
118. Sandercock P, Counsell C, Tseng MC. Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD000119.pub3]
119. Sandercock PAG, Gibson LM, Liu M. Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD000248.pub2]
120. Sandercock PAG, Soane T. Corticosteroids for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD000064.pub2]
121. Sandercock PAG, Counsell C, Tseng MC, Cecconi E. Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2014, Issue 3. [DOI: 10.1002/14651858.CD000029.pub3]
122. Sapronov NS, Bul'on VV, Kuznetsova NN, Selina EN. The neuroprotector effect of a new taurine derivative on a model of compression spinal cord trauma in rats [Russian]. Eksperimental'naia i Klinicheskaia Farmakologiia 2005;68(6):45-8.
123. Schauer E, Wronski R, Patockova J, Moessler H, Doppler E, Hutter-Paier B, et al. Neuroprotection of Cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window. Journal of Neural Transmission 2006;113(7):855-68.
124. Schunemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. Available from www.cochrane-handbook.org. The Cochrane Collaboration.
125. Shu LLS, San Jose CZ, Pasco PP. The efficacy and safety of cerebrolysin in acute hemorrhagic stroke: a meta analysis. Cerebrovascular Diseases 2012;34(Suppl 1):36.
126. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. New England Journal of Medicine 2007;357(6):562-71.
127. Suslina ZA, Varakin YY, Vereshchagin NV. Clinical and epidemiological research as a perspective direction of cerebral pathology study (the first report) [Clinico-epidemiologicheskiye issledovaniya - perspectivnoye napravleniye izucheniya cerebralnoi patologii (soobscheniye pervoiye)]. Annals of Neurology 2009;3:4-11.
128. Tan Y, Liu M, Wu B. Puerarin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004955.pub2]
129. Bath PM, Iddenden R, Bath FJ, Orgogozo JM, Tirilazad International Steering Committee. Tirilazad for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002087]
130. Vilenski BS, Iakhno NN. The problem of cerebral stroke: its contemporary state. Vestnik Rossi sko Akademii Meditsinskikh Nauk 2006;9-10:18-24.
131. Visvanathan A, Dennis M, Whiteley W. Parenteral fluid regimens for improving functional outcome in people with acute stroke. Cochrane Database of Systematic Reviews 2015, Issue 9. [DOI: 10.1002/14651858.CD011138.pub2]
132. Wardlaw JM, Koumellis P, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD000514.pub3]
133. Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD000213.pub3]
134. World Health Organization. The Atlas of Heart Disease and Stroke. www.who.int/cardiovascular_diseases/resources/atlas/en/ (accessed November 2014).
135. National Essential Medicines Lists. www.who.int/selection_medicines/country_lists (accessed 12 August 2016).
136. Wong GK, Zhu XL, Poon WS. Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study. Acta Neurochirurgica Supplement 2005;95:59-60.
137. Yang W, Hao Z, Zhang S, Dong W, Wu T, Liu GJ, et al. Mailuoning for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007028.pub2]
138. Zeng X, Liu M, Yang Y, Li Y, Asplund K. Ginkgo biloba for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003691.pub2]
139. Zhang CL, Chopp M, Cui YS, Wang L, Zhang RL, Zhang L, et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. Journal of Neuroscience Research 2010;88(15):3275-81.
140. Zhuo Q, Yang X, Wu T, Liu G, Zhou L. Tongxinluo capsule for acute stroke. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD004584.pub2]
141. Ziganshina LE, Abakumova T, Kuchaeva A. Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD007026.pub2]
142. Ziganshina LE, Abakumova T, Kuchaeva A. Cerebrolysin for acute ischaemic stroke. International Journal of Risk and Safety in Medicine 2010;22(4):179-93.
143. Ziganshina LE, Abakumova TR. Cerebrolysin for acute ischemic stroke. Vestnik Rossi Akademii Meditsinskikh Nauk 2013;1:21-9.
144. Ziganshina LE, Abakumova T. Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD007026.pub3]